Evidence map›Paper›PMID 21487763›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2011

Comparison of culture media for detection of Acinetobacter baumannii in surveillance cultures of critically-ill patients.

A O Ajao, G Robinson, M S Lee, T D Ranke, R A Venezia, J P Furuno, A D Harris, J K Johnson

Abstract readComparative Study
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Guideline
  2. Detection and Isolation of PsychrotrophicFoods (Basel, Switzerland) · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. New Agents Are Coming, and So Is the Resistance.Antibiotics (Basel, Switzerland) · 2024
    Review
  8. Article
  9. Characterization ofBiology · 2022
    Article
  10. Article
  11. Use of fluoroquinolones is the single most important risk factor for the high bacterial load in patients with nasal and gastrointestinal colonization by multidrug-resistant Acinetobacter baumannii.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2015
    Article
  12. Article
  13. Laboratory evaluation of different agar media for isolation of carbapenem-resistant Acinetobacter spp.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2014
    Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

A O AjaoDepartment of Epidemiology and Public Health, University of Maryland School of Medicine, 685 W. Baltimore St, Baltimore, MD 21201, USA. aajao@epi.umaryland.edu
G Robinson
M S Lee
T D Ranke
R A Venezia
J P Furuno
A D Harris
J K Johnson
University of Maryland, Baltimore · US

Funding

Clinical Research Career Development (RMI)K12RR023250 · NCRR · UNIVERSITY OF MARYLAND BALTIMORE · PI SHULDINER, ALAN R. · 2005 to 2009
$13.3M
Epidemiology of imipenem-resistant P.aeruginosaR01AI060859 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI HARRIS, ANTHONY D · 2005 to 2013
$1.9M
K24 Clinical Research in Antimicrobial Resistance and Hospital EpidemiologyK24AI079040 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI HARRIS, ANTHONY D · 2009 to 2018
$1.8M
Epidemiology of resistant bacteria in acute-care and long-term care facilitiesK01AI071015 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI FURUNO, JON P · 2008 to 2012
$757k
NCRR NIH HHS 1K12RR023250-03NCRR NIH HHS K12 RR023250NIAID NIH HHS 1K01AI071015-03NIAID NIH HHS 1K24AI079040NIAID NIH HHS 2R01AI060859-05NIAID NIH HHS K01 AI071015NIAID NIH HHS K24 AI079040NIAID NIH HHS R01 AI060859PHS HHS HHSA290200600020
6 · The paper itself

Abstract

The objective of this study was to evaluate the performance of CHROMagar Acinetobacter when compared to sheep blood agar, MacConkey agar and MacConkey agar with 6 μg/ml of imipenem for the detection of A. baumannii in surveillance cultures of hospitalized patients. We utilized peri-anal swabs and sputum samples from patients admitted to the University of Maryland Medical Center ICUs from December 7 through December 21, 2009. Samples were plated onto four media in the following order: (1) 5% sheep blood agar (SBA), (2) MacConkey agar, (3) MacConkey agar with 6 μg/ml of imipenem, and (4) CHROMagar Acinetobacter (CHROMagar). SBA was the gold standard to which all media was compared. There were 165 samples collected during the study period. SBA and CHROMagar detected 18 of 18 (100%) Acinetobacter and 11 of 11 (100%) MDR-A. baumannii. MacConkey agar detected 16 of 18 (89%) Acinetobacter and 10 of 11 (91%) MDR- A. baumannii while MacConkey agar with 6 μg/ml imipenem detected 9 of 11 (82%) MDR-A. baumannii. CHROMagar did not differentiate MDR- A. baumannii from non-MDR-A. baumannii. CHROMagar may be useful for rapid detection of patients with MDR-A. baumannii if improved upon to better select for MDR-A. baumannii.

Indexed as

Acinetobacter baumanniiAcinetobacter InfectionsAnal CanalAnti-Bacterial AgentsBacteriological TechniquesCohort StudiesCritical IllnessCulture MediaDrug Resistance, Multiple, BacterialHumansImipenemInfection ControlIntensive Care UnitsSensitivity and SpecificitySputumAnti-Bacterial AgentsCulture MediaImipenem

Identifiers

PMID21487763
PMCPMC3660032
OpenAlexW2017674604

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.